Longeveron (LGVN) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Longeveron is the larger company by market cap ($7.9 million vs $6.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGVN | NRSN |
|---|---|---|
| Share price | $2.48 | $3.66 |
| Market cap | $7.91M | $6.94M |
| 1-day change | +4.64% | -2.14% |
| EPS (TTM) | $-9.90 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.30 | $26.64 |
| 52-week low | $2.30 | $3.56 |
| Distance from 52-week high | -79.84% | -86.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2369.76% | +2559.29% |
| Average volume | 93.11K | 21.49K |
| Shares outstanding | 3.04M | 1.90M |
| Employees | 38 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
LGVN vs NRSN FAQ
Which is bigger, Longeveron or NeuroSense Therapeutics?
Longeveron (LGVN) is larger, with a market capitalization of $7.91M compared with $6.94M for NeuroSense Therapeutics (NRSN).
Are Longeveron and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.